Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M89,644Revenue $M25,711Net Margin (%)9.9Z-Score2.4
Enterprise Value $M93,964EPS $2.0Operating Margin %14.4F-Score4
P/E(ttm))44.4Cash Flow Per Share $0Pre-tax Margin (%)12.7Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %10.5Quick Ratio0.9Cash flow > EarningsY
Price/Sales3.55-y EBITDA Growth Rate %-9.0Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-31.8ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %3.9Insider Buy (3m)0ROE % (ttm)11.0Less Shares Outstanding y-yN
Payout Ratio %174Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 70.52-2%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 70.52-2%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 70.52-2%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 70.52-2%Sold Out0
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 70.5210%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 70.5210%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 70.5210%New holding, 95518 sh.95,518
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 70.5210%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 70.5230%Reduce -40.32%106,975
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 70.5230%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 70.5240%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 70.5240%Reduce -81.87%68,000
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 70.5238%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 70.5238%Sold Out0
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 70.5249%Reduce -38.8%932,000
AZNCharles Brandes 2012-12-31 Buy 1.2%$44.34 - $48.9
($46.77)
$ 70.5251%New holding, 2188735 sh.2,188,735
AZNJohn Hussman 2012-12-31 Reduce-0.56%$44.34 - $48.9
($46.77)
$ 70.5251%Reduce -24.49%1,523,000
AZNDavid Dreman 2012-12-31 Reduce-0.2%$44.34 - $48.9
($46.77)
$ 70.5251%Reduce -52.4%152,504
AZNJoel Greenblatt 2012-12-31 Reduce-0.12%$44.34 - $48.9
($46.77)
$ 70.5251%Reduce -31.34%83,972
AZNJoel Greenblatt 2012-09-30 Add0.12%$44.91 - $48.35
($46.83)
$ 70.5251%Add 42.7%122,294
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Mario Gabelli 2014-06-3040,40000.02New Buy
AZN George Soros 2014-06-30150,0000.010.08New Buy
AZN - CALLDaniel Loeb 2014-06-301,000,0000.080.91
AZN John Hussman 2014-06-30223,5000.021.3-1.97%
AZN David Dreman 2014-06-30117,8320.010.66-13%
AZN Charles Brandes 2014-06-30386,0580.030.35-71.06%
AZN Joel Greenblatt 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


      More From Other Websites
      AstraZeneca and Mitsubishi Tanabe link on diabetes research Aug 20 2014
      US Department Of Justice Ends Investigation Of AstraZenca Trial Aug 19 2014
      This stock may be hazardous to your financial health Aug 19 2014
      Will Roche (RHHBY) Buy the Remaining Stake in Chugai? Aug 19 2014
      Novo Nordisk to Pay Fine, Tresiba in Focus Aug 19 2014
      Pfizer Submits Palbociclib Marketing Application to the FDA Aug 19 2014
      Foreign Firms Worry About Being Caught Up In Inversion Crackdown Aug 19 2014
      [video] AstraZeneca Allowed to Market Heart Drug as Federal Probe Closed Aug 19 2014
      Eli Lilly-Boehringer's Insulin Drug Gets Tentative FDA Nod Aug 19 2014
      How Will AstraZeneca (AZN) Stock Respond To U.S. Clearing Heart Drug Trial? Aug 19 2014
      The Negative Impact Of Pfizer's Mergers And Budget Cuts On Cancer R&D Aug 19 2014
      The Zacks Analyst Blog Highlights: Tesla Motors, CarMax, O'Reilly Automotive, Fox Factory Holding... Aug 19 2014
      7:02 am AstraZeneca: US Department of Justice closes investigation into PLATO clinical trial for... Aug 19 2014
      US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA Aug 19 2014
      Will The US Block Shire PLC’s Buyout And Prevent A Takeover Of AstraZeneca plc? Aug 19 2014
      U.S. clears AstraZeneca over heart drug trial Aug 19 2014
      AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients... Aug 19 2014
      United States Department of Justice closes investigation into PLATO clinical trial for Brilinta Aug 19 2014
      U.S. clears AstraZeneca over heart drug trial Aug 19 2014
      AstraZeneca's Asthma Drug in Focus, Phase III Study Initiated Aug 18 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide